REFERENCES
- W. König, J. Sandow, R. Geiger: Structure function relationships of LHRH, R. Walter and J. Meienhofer (herausg.): Peptides: Chemistry, Structure and Biology. Ann Arbor Science Publishers, 1975; 883–887
- C.F. Blackard, R.P. Doc. G.T. Meilinger et al.: Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate. Cancer, 1970; 26: 249–256
- H.C. Bumpus: Carcinoma of the prostate, a clinical study of one thousand cases. Sure Gynaecol Obstet 1926; 43: 15
- E.D. Crawford, M.A. Eisenberger, D.O. McLeod et al.: A controlled trial of Leuprolide with and without Flutamide in prostatic carcinoma. New Engl. J. Med. 1989; 321: 419
- J.L. Emmet, L.F. Greene and A. Papantoniou: Endocrine therapy in carcinoma of the prostate gland, 10 year survival studies. J. Urology. 1960; 83: 471
- N. Faure, F. Labrie: Assessment of clinical efficacy and safety of HOE766 (busereline) in carcinoma of the prostate (study 21). (An open uncontrolled Phase II investigation on patients followed up on the emergency drug release regulations) Hoechst Canada in house report study (study 411), Montreal, February 1983
- P.O. Hedlund, H. Gustafson, S. Sjögren: Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. A follow-up of 212 randomised patients. Scand. J. Urol. Nephrol. 1980; suppl. 55: 103 – 105
- R.P. Huben, G.P. Murphy and the investigators of the National Prostatic Cancer Project: A comparison of diethylstilboestrol or orchiectomy with buserelin and with methotrexate plus diethylstilboestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate. Cancer, 1988; 62: 1881 – 1887
- P. Iversen, S. Suciu, R. Sylvester, I. Christensen and L. Denis: Zoladex and Flutamide versus orchiectomy in the treatment of advanced prostatic cancer. Cancer supplement, 1990; 66: 61 – 73
- D. Kirchheim: Results and experience with the androgen ablation therapy: current trends in the USA, H. Klosterhalfen (ed.) Endocrine Management of Prostatic Cancer (in series). New Developments in Biosciences, 1988; 4: 123
- J.G.M Klijn, H.J. de Voogt, F.H. Schröder et al.: Letters to the editor: Combined treatment with buserelin and cyproterone acetate in metastatic prostatic carcinoma. The Lancet, 1985; August 31
- G.P. Murphy, J.F. Gaeta, J. Pickren, Z. Wajsman: Current status of classification and staging of prostate cancer. Cancer, 1980; 45, 1889 – 1895
- R.M. Nesbit and W.C. Baum: Endocrine control of prostatic carcinoma. Clinical and statistical survey of 1818 cases. J.A.M.A., 1950; 143: 1317
- R.M. Nesbit and R.T. Plumb: Prostatic carcinoma, a follow-up on 795 patients treated prior to endocrine era and comparison of survival rates between these and patients treated by endocrine therapy. Surgery, 1946; 20: 263
- M.S. Soloway: the importance of prognostic factors in advanced prostate cancer. Cancer suppl. 1990; 66; 11 – 15
- H.J. de Voogt, P.H. Smith, M. Pavone-Macaluso et al.: Cardiovascular side-effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: Results from European organization for Research on Treatment of Cancer, trials 30761 and 30762. J. Urol. 1986; 135: 303 – 307
- The Veterans Administration Cooperative Urological Research Group: Carcinoma of the prostate: treatment comparisons. J. Urol. 1967; 98; 516 – 522
- The Leuprolide Study Group: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The New England Journal of Medicine, 1984; 311: 1281 – 1286